In a remarkable scientific breakthrough, Brazilian researchers have identified a molecule in scorpion venom that may help treat breast cancer. The findings were presented at FAPESP Week France by a team from the University of São Paulo.
The molecule, BamazScplp1, was extracted from the Brotheas amazonicus scorpion native to the Amazon. Lab tests showed that it demonstrated anti-cancer properties similar to paclitaxel, a widely used chemotherapy drug.
Safer, Scalable Production via Gene Tech
Instead of harvesting venom directly from scorpions, the researchers used a method called heterologous expression. This involves inserting the gene responsible for producing the protein into microorganisms like yeast or bacteria to generate it safely and at scale.
“We now aim to produce this molecule in the lab using Pichia pastoris, a yeast commonly used in genetic research,” said project coordinator Prof. Eliane Candiani Arantes.
Test Results Mirror Chemotherapy Effects
The study revealed that BamazScplp1 induced cancer cell death, primarily through necrosis, much like paclitaxel. This mechanism is also seen in molecules from other scorpion species, according to the researchers.
The Global Impact of Breast Cancer
As per the World Health Organization, breast cancer is the most common cancer among women and the second most common globally. In 2022, there were 2.3 million new cases and 670,000 deaths worldwide.
A Nature Medicine study predicts that by 2050, these figures could rise to 3.2 million new cases and 1.1 million deaths annually.
Hope for the Future
With more research and successful trials, the scorpion venom-derived peptide could offer a novel and natural alternative to chemotherapy, paving the way for more targeted and potentially less toxic cancer treatments.
